164 related articles for article (PubMed ID: 3903584)
1. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
2. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
5. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemotherapy in advanced ovarian cancer: initial experience in an Indian set-up.
Charak BS; Agarwala S; Gopal R; Advani SH; Nadkarni KS; Pai VR; Saikia TK; Desai PB
Indian J Cancer; 1989 Jun; 26(2):85-91. PubMed ID: 2592001
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
8. [Clinical application of subrenal capsule assay in ovarian cancer].
Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
[TBL] [Abstract][Full Text] [Related]
9. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
10. Subrenal capsule assay in choosing cytostatics for gynaecological tumours.
Mäenpää J; Grönroos M; Kangas L
Ann Chir Gynaecol Suppl; 1985; 199():28-30. PubMed ID: 3864390
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
13. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
[TBL] [Abstract][Full Text] [Related]
15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
16. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Covens A; Blessing J; Bender D; Mannel R; Morgan M;
Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]